<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561755</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 10-1108</org_study_id>
    <secondary_id>HS#: 11-02029</secondary_id>
    <nct_id>NCT01561755</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy</brief_title>
  <official_title>A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David M. Simpson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Intravenous Immunoglobulin (IVIG) is an
      effective treatment for HIV associated myelopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether or not intravenous immunoglobulin (lVlg),
      brand name Privigen, is effective in treating a disorder called HIV-associated myelopathy
      (HIVM). This drug is currently not approved by the Food and Drug Administration (FDA) for
      treating this disorder.

      HIVM is a spinal cord disease that occurs at any stage of HIV infection. It is not known what
      causes this condition, but symptoms can include weakness in the lower body and problems with
      frequent urination or problems with bowel function, trouble walking or performing sexually.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficulty with enrollment
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Strength Scores</measure>
    <time_frame>at 2 months</time_frame>
    <description>Strength score as measured by pounds of force sustained in lower extremity strength.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Walking Test</measure>
    <time_frame>at 2 months</time_frame>
    <description>2 minute walking test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Function</measure>
    <time_frame>2 months</time_frame>
    <description>0 = Normal bladder function, 1 = Asymptomatic on current treatment, 2 = Urinary frequency, hesitancy, urgency, with no incontinence, 3 = Occasional urinary incontinence (once or more during the last month but not every week) or intermittent catheterization, 4 = Frequent urinary incontinence, or occasional incontinence despite regular catheterization, 5 = Daily urinary incontinence or permanent catheter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bowel Function</measure>
    <time_frame>2 months</time_frame>
    <description>0 = No bowel problems, 1 = Asymptomatic on current drug tx or constipation not requiring any tx, 2 = Constipation requiring laxative or suppositories or fecal urgency, 3 = Constipation requiring the use of an enema, 4 = Constipation requiring manual evacuation of stools or occasional fecal incontinence (once or more during the last month but not every week, 5 = Weekly fecal incontinence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hughes Function Score</measure>
    <time_frame>at 2 months</time_frame>
    <description>0 = Normal strength; 1 = minor symptoms but capable of running; 2 = The subject is able to walk 30 ft. but unable to run; 3 = The subject is able to walk 30 ft. with the assistance of one person; 4 = A walker or cane; 5 = The subject is unable to walk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impression of Change Score - Participant</measure>
    <time_frame>at 2 months</time_frame>
    <description>The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment 1. Marked improvement; 2 Moderate Improvement; 3 Minimal Improvement; 4 No Change; 5 Minimal Worsening; 6 Moderate Worsening; 7 Marked worsening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impression of Change Score - Clinician</measure>
    <time_frame>at 2 months</time_frame>
    <description>The clinician measure of Global Impression of Change reflects the clinician's view about the efficacy of treatment as measured by 1. Marked improvement; 2 Moderate Improvement; 3 Minimal Improvement; 4 No Change; 5 Minimal Worsening; 6 Moderate Worsening; 7 Marked worsening</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>HIV-associated Myelopathy</condition>
  <arm_group>
    <arm_group_label>Intravenous Immunoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 2gr/kg over 2 days of saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Immunoglobulin</intervention_name>
    <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
    <arm_group_label>Intravenous Immunoglobulin</arm_group_label>
    <other_name>Privigen®</other_name>
    <other_name>IVIG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - 2gr/kg over 2 days of saline</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented history of HIV infection.

          -  Age ≥ 18

          -  Males and females are eligible. Subjects must agree to practice birth control or
             abstinence. Females of child-bearing potential must have a negative urine pregnancy
             within 14 days prior to study entry.

          -  Adequate baseline organ function including the following laboratory values within 14
             days prior to study entry:

          -  Adequate liver function with ALT, AST and alkaline phosphatase ≤ 5 times upper limit
             of normal (ULN).

          -  Total bilirubin ≤ 2.5 mg/dL Creatinine &lt; 2.3 Serum vitamin B12 level ≥ 200 pg/ml

          -  Diagnosis of HIVM by a neurologist - defined as:

          -  - Presence of at least two of the following symptoms:

          -  - Paresthesias and/or numbness in the lower extremities or in all four limbs; Weakness
             of the limbs, with predominance in the lower extremities; Unsteady, stiff or
             uncoordinated gait; Sensation of electrical shock through the back or the legs upon
             flexion of the neck (L'Hermitte's sign); Stiffness or spasm in the lower extremities;
             Urinary frequency, urgency, incontinence or retention; Fecal incontinence or
             retention; Sexual dysfunction with erectile impairment in men;

          -  - Presence of at least two of the following neurologic signs:

          -  - Reduction in vibratory or position sensation in the lower extremities; Hyperactive
             deep tendon reflexes; Abnormal response to plantar stimulation (Babinski sign);
             Presence of L'Hermitte sign (electrical-type sensation down the back, provoked by
             flexion of the neck); Weakness in the lower extremities or in all four limbs; Spastic
             or ataxic gait

          -  Antiretroviral regimen stable 2 months prior to the entry of the study.

        Exclusion Criteria:

          -  Presence of acute, active, opportunistic infection, except oral thrush, orogenital or
             rectal herpes and MAI bacteremia within 2 weeks before randomization.

          -  Evidence of another contributing cause for myelopathy.

          -  Women who are pregnant, breast-feeding or planning a pregnancy.

          -  Active abuse of drugs or alcohol, which in the opinion of the investigator would
             interfere with the subject's ability to comply with the protocol.

          -  Any neurologic or systemic conditions, which in the opinion of the investigator would
             interfere with the evaluation of the subject.

          -  Presence of significant cardiac, pulmonary or renal disease that would place the
             subject at risk for the fluid and protein load of IVIg.

          -  History of hypersensitivity to immunoglobulin, or IgA deficiency; Vaccination with
             live viruses within the past 90 days; Patients receiving IVIg or other
             immunomodulatory agent (cyclosphosphamide, azathioprine, corticosteroids, tacrolimus,
             cyclosporine, OKT3, plasma exchange, alpha, beta or gamma interferon) within the past
             3 months.

          -  Patients in whom muscle dynamometry can not be performed for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Simpson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2012</study_first_posted>
  <results_first_submitted>March 6, 2018</results_first_submitted>
  <results_first_submitted_qc>April 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>David M. Simpson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>HIV associated myelopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from three main sources: the clinical NeuroAIDS practices of the investigators; pre-existing observational research studies (Manhattan HIV Brain Bank and the CNS HIV Antiretroviral Effects Research (CHARTER)); and via a referral network of regional HIV care providers. for a total of four years 2012-2016.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Immunoglobulin</title>
          <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Saline 2gr/kg over 2 days of saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intravenous Immunoglobulin</title>
          <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Saline 2gr/kg over 2 days of saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" lower_limit="29" upper_limit="69"/>
                    <measurement group_id="B2" value="58" lower_limit="29" upper_limit="68"/>
                    <measurement group_id="B3" value="48" lower_limit="29" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participant with undetectable Viral Load</title>
          <description>Number of participants with undetectable viral load &lt;20 copies/ml</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>mean CD4+</title>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="620" spread="223"/>
                    <measurement group_id="B2" value="564" spread="270"/>
                    <measurement group_id="B3" value="592" spread="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Strength Scores</title>
        <description>Strength score as measured by pounds of force sustained in lower extremity strength.</description>
        <time_frame>at 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin</title>
            <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline 2gr/kg over 2 days of saline</description>
          </group>
        </group_list>
        <measure>
          <title>Strength Scores</title>
          <description>Strength score as measured by pounds of force sustained in lower extremity strength.</description>
          <units>pounds of force</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hip Flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="32.7"/>
                    <measurement group_id="O2" value="1.9" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Knee Flexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="14.4"/>
                    <measurement group_id="O2" value="10.3" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ankle Dorsiflexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="8.2"/>
                    <measurement group_id="O2" value="-6.0" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower extremity - sum of all three</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="49.2"/>
                    <measurement group_id="O2" value="6.2" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Walking Test</title>
        <description>2 minute walking test</description>
        <time_frame>at 2 months</time_frame>
        <population>One participant in placebo group in wheelchair and unable to complete the walking test</population>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin</title>
            <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline 2gr/kg over 2 days of saline</description>
          </group>
        </group_list>
        <measure>
          <title>Walking Test</title>
          <description>2 minute walking test</description>
          <population>One participant in placebo group in wheelchair and unable to complete the walking test</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.49" spread="42.57"/>
                    <measurement group_id="O2" value="112.08" spread="102.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Function</title>
        <description>0 = Normal bladder function, 1 = Asymptomatic on current treatment, 2 = Urinary frequency, hesitancy, urgency, with no incontinence, 3 = Occasional urinary incontinence (once or more during the last month but not every week) or intermittent catheterization, 4 = Frequent urinary incontinence, or occasional incontinence despite regular catheterization, 5 = Daily urinary incontinence or permanent catheter</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin</title>
            <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline 2gr/kg over 2 days of saline</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Function</title>
          <description>0 = Normal bladder function, 1 = Asymptomatic on current treatment, 2 = Urinary frequency, hesitancy, urgency, with no incontinence, 3 = Occasional urinary incontinence (once or more during the last month but not every week) or intermittent catheterization, 4 = Frequent urinary incontinence, or occasional incontinence despite regular catheterization, 5 = Daily urinary incontinence or permanent catheter</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="2.5" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bowel Function</title>
        <description>0 = No bowel problems, 1 = Asymptomatic on current drug tx or constipation not requiring any tx, 2 = Constipation requiring laxative or suppositories or fecal urgency, 3 = Constipation requiring the use of an enema, 4 = Constipation requiring manual evacuation of stools or occasional fecal incontinence (once or more during the last month but not every week, 5 = Weekly fecal incontinence</description>
        <time_frame>2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin</title>
            <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline 2gr/kg over 2 days of saline</description>
          </group>
        </group_list>
        <measure>
          <title>Bowel Function</title>
          <description>0 = No bowel problems, 1 = Asymptomatic on current drug tx or constipation not requiring any tx, 2 = Constipation requiring laxative or suppositories or fecal urgency, 3 = Constipation requiring the use of an enema, 4 = Constipation requiring manual evacuation of stools or occasional fecal incontinence (once or more during the last month but not every week, 5 = Weekly fecal incontinence</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="2.07" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hughes Function Score</title>
        <description>0 = Normal strength; 1 = minor symptoms but capable of running; 2 = The subject is able to walk 30 ft. but unable to run; 3 = The subject is able to walk 30 ft. with the assistance of one person; 4 = A walker or cane; 5 = The subject is unable to walk.</description>
        <time_frame>at 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin</title>
            <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline 2gr/kg over 2 days of saline</description>
          </group>
        </group_list>
        <measure>
          <title>Hughes Function Score</title>
          <description>0 = Normal strength; 1 = minor symptoms but capable of running; 2 = The subject is able to walk 30 ft. but unable to run; 3 = The subject is able to walk 30 ft. with the assistance of one person; 4 = A walker or cane; 5 = The subject is unable to walk.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3.2" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impression of Change Score - Participant</title>
        <description>The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment 1. Marked improvement; 2 Moderate Improvement; 3 Minimal Improvement; 4 No Change; 5 Minimal Worsening; 6 Moderate Worsening; 7 Marked worsening</description>
        <time_frame>at 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin</title>
            <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline 2gr/kg over 2 days of saline</description>
          </group>
        </group_list>
        <measure>
          <title>Impression of Change Score - Participant</title>
          <description>The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment 1. Marked improvement; 2 Moderate Improvement; 3 Minimal Improvement; 4 No Change; 5 Minimal Worsening; 6 Moderate Worsening; 7 Marked worsening</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="3.7" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impression of Change Score - Clinician</title>
        <description>The clinician measure of Global Impression of Change reflects the clinician's view about the efficacy of treatment as measured by 1. Marked improvement; 2 Moderate Improvement; 3 Minimal Improvement; 4 No Change; 5 Minimal Worsening; 6 Moderate Worsening; 7 Marked worsening</description>
        <time_frame>at 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intravenous Immunoglobulin</title>
            <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Saline 2gr/kg over 2 days of saline</description>
          </group>
        </group_list>
        <measure>
          <title>Impression of Change Score - Clinician</title>
          <description>The clinician measure of Global Impression of Change reflects the clinician's view about the efficacy of treatment as measured by 1. Marked improvement; 2 Moderate Improvement; 3 Minimal Improvement; 4 No Change; 5 Minimal Worsening; 6 Moderate Worsening; 7 Marked worsening</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="4" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intravenous Immunoglobulin</title>
          <description>Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Saline 2gr/kg over 2 days of saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mild headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment difficult with the widespread availability of IVIG which can be prescribed in an “off-label” fashion, the low incidence of new HIVM cases and a reluctance of this patient population to undergo randomization.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. David Simpson</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-8748</phone>
      <email>david.simpson@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

